DJIA 15,914.74 -99.64 -0.62%
NASDAQ 4,283.59 14.83 0.35%
S&P 500 1,851.86 -0.35 -0.02%
market minute promo

Vertex Pharmaceuticals (NASDAQ: VRTX)

81.73 1.59 (1.98%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

VRTX $81.73 1.98%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $82.26
Previous Close $80.14
Daily Range $80.25 - $84.06
52-Week Range $79.44 - $143.45
Market Cap $20.1B
P/E Ratio -34.69
Dividend (Yield) $0.00 (0.0%)
Volume 4,115,279
Average Daily Volume 2,975,509
Current FY EPS -$2.28




Drug Makers

Vertex Pharmaceuticals (VRTX) Description

The Company is in the business of discovering, developing and commercializing small molecule drugs for the treatment of serious diseases. Website:

News & Commentary

Vertex Pharmaceuticals Inc. Dropped 26% in January -- Here's Why

The market dumped everything related to biotechnology, and Vertex got caught up in the storm.

Biotech Stock Roundup: Alexion, Regeneron Miss Estimates; Setback for CTI BioPharma

Vertex (VRTX) Down on CRL for Kalydeco Label Expansion

Vertex Pharmaceuticals Has Great Upside Potential

Here's Why Shares Of Vertex Pharmaceuticals Tumbled

Health Care Sector Update for 02/05/2016: JNJ, PFE, ABT, MRK, AMGN, IMMU, VRTX

Health Care Sector Update for 02/05/2016: VRTX, DHRM

Vertex Pharmaceuticals Inc.'s Q4 Revenues Surge on New Drug

The biotech's newest drug, cystic fibrosis treatment Orkambi, is now its top-selling asset.

Ignore Regeneron Pharmaceuticals, Inc: Here Are 3 Better Buys Right Now

Thinking about investing in Regeneron? Here are three names you might want to consider instead.

Vertex A Buy On Orkambi Revenue And Pipeline

See More VRTX News...

VRTX's Top Competitors

VRTX $81.73 (1.98%)
Current stock: VRTX
CELG $103.16 (2.65%)
Current stock: CELG
AMGN $144.81 (1.15%)
Current stock: AMGN
BIIB $252.20 (0.88%)
Current stock: BIIB